Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

Despite high remission rates following CAR-T cell therapy in B-ALL, relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and CD22 may reduce the likelihood of antigen loss, thus improving sustained...

Full description

Bibliographic Details
Main Authors: Haiying Qin, Sneha Ramakrishna, Sang Nguyen, Thomas J. Fountaine, Anusha Ponduri, Maryalice Stetler-Stevenson, Constance M. Yuan, Waleed Haso, Jack F. Shern, Nirali N. Shah, Terry J. Fry
Format: Article
Language:English
Published: Elsevier 2018-12-01
Series:Molecular Therapy: Oncolytics
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770518300305

Internet

http://www.sciencedirect.com/science/article/pii/S2372770518300305

Similar Items